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Rojas and colleagues have presented an exciting
paper demonstrating yet another relevant preclinical
setting in which the mesenchymal stromal cell has a
potential therapeutic application. What is particularly
interesting about this study is that it addresses a
disease, blood-borne systemic sepsis, which has
multiple complex host responses and involves a
variety of disparate organs and immune cell types.
Here, the authors focus on how this injury relates
more specifically to the lung, with quite dramatic
improvements in several assessed injury parameters.
Where does this latest demonstration of mesenchymal
stromal cell efficacy leave us with regard to getting
these cell therapies to the acute respiratory distress
syndrome patient?While antibiotics may go some way towards alleviatingThe mesenchymal stromal cell (MSC) as a proposed
treatment for acute respiratory distress syndrome (ARDS)
appears to be rapidly approaching the moment of truth
for any new drug. We have the disease, we have the
medicine, and we have the preclinical data – now for the
important part. Rojas and colleagues’ paper informs us of
another possible application of the MSC: treatment of
ARDS as a consequence of a systemic infection [1].
Of note, especially in the acute clinical setting of
ARDS, is the fact that this MSC is administered directly
from cryopreservation. There has been much recent
debate as to whether a wake-up period is essential for
the beneficial effects seen with MSCs in injury models,
and it is heartening to see that an off-the-shelf product
such as MultiStem (Athersys, Cleveland, OH, USA) can
be used in a rapid, multiorgan failure setting such as* Correspondence: daniel.otoole@nuigalway.ie
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2014sepsis. This observation is of enormous importance be-
cause there are now up to 10 years of promising findings
in models that have utilized freshly harvested passaging
MSCs, with some trepidation as to whether a −150°C
freezer stock of MSCs in the intensive care department
was ever likely to be the eventual outcome. While confirm-
ing some findings [2], this is also a direct contradiction of
some earlier work that failed to demonstrate adequate
therapeutic potential of MSCs immediately after thaw from
cryostorage [3].
There are, however, still some concerns and possible
missing pieces in this jigsaw leading to a picture of a per-
fected translation to the clinic. Firstly, this study utilizes
bacteria-derived lipopolysaccharide as the injurious agent.
Whilst this recapitulates many of the host inflammatory
responses in a sepsis setting, it does not address the
additional necessity of bacteria clearance from the host.
this concern, an injury model utilizing clinically isolated
pathogens with administration of a relevant broad-
spectrum antibiotic would raise confidence immensely in
the MultiStem product’s real-world efficacy. Indeed, recent
work has begun to address the direct antibacterial effects
of the MSC alongside its ability to enhance the function of
macrophages and perhaps other leukocyte populations
[4,5]. Furthermore, and while not a comment directed at
this study of systemic sepsis, the persistence of Escherichia
coli (or its products) as the preferred causative of pneumo-
nia in lung injury research is perhaps occluding the reality
of multiple, indeed often unidentified, pathogen involve-
ment in the aetiology of pneumonia-induced ARDS.
Another caveat is that while in certain aspects it is
appealing due to possible enhanced safety and a lower
required dose of MSCs, intratracheal (or in this case the
even more invasive intrabronchial) administration of any
appreciable liquid volume of therapeutic may be a talled Central Ltd. The licensee has exclusive rights to distribute this article, in any
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fluid infiltration into the lung air space. Adding more li-
quid to an already poorly performing lung may be a risk
the physician is unwilling to take. Intratracheal/intra-
bronchial studies offer a wealth of information with
regards to mechanism of action, but the success thus far
of numerous studies using the intravenous route would
appear to make this the most promising with respect to
ultimate delivery to the patient.
Despite this, preclinical validation of any possible
therapeutic for the devastating condition of sepsis/ARDS
is to be welcomed, and we look forward intently to
following up the MultiStem MSC as it forges it way
towards success in the true clinical setting.
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